Details of the Drug

General Information of Drug (ID: DMLUA9D)

Drug Name

Simeprevir

Synonyms

TMC436

Indication

Disease Entry	ICD 11	Status	REF
Chronic HCV-1 infection	1E51.1	Approved	[1], [2]

Therapeutic Class

Antiinfective Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

749.9

Topological Polar Surface Area (xlogp)

4.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 41 hours [4]
Metabolism: The drug is metabolized via the hepatic [5]

Chemical Identifiers

Formula: C38H47N5O7S2
IUPAC Name: (1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide
Canonical SMILES: CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC
InChI: InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1
InChIKey: JTZZSQYMACOLNN-VDWJNHBNSA-N

Cross-matching ID

PubChem CID: 24873435
ChEBI ID: CHEBI:134743
CAS Number: 923604-59-5
DrugBank ID: DB06290
TTD ID: D00TLP
VARIDT ID: DR00014
INTEDE ID: DR1484
ACDINA ID: D00623

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)	TTHC7JD	POLG_HCV1	Modulator	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Simeprevir

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Boceprevir	DMBSHMF	Major	Decreased metabolism of Simeprevir caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[36]
GS-5885	DMSL3DX	Major	Decreased clearance of Simeprevir due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[37]
GS-9857	DMYU6P5	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by GS-9857.	Hepatitis virus infection [1E50-1E51]	[38]
-----------

Coadministration of a Drug Treating the Disease Different from Simeprevir (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[39]
Arn-509	DMT81LZ	Major	Increased metabolism of Simeprevir caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[40]
Gilteritinib	DMWQ4MZ	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[39]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Simeprevir caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[36]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[41]
Tucatinib	DMBESUA	Major	Decreased metabolism of Simeprevir caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Revefenacin	DMMP5SI	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[42]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Simeprevir caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[43]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Simeprevir caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Ripretinib	DM958QB	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[36]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[44]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[45]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Simeprevir caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Etravirine	DMGV8QU	Major	Increased metabolism of Simeprevir caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[42]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Simeprevir caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[43]
Levamlodipine	DM92S6N	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Levamlodipine.	Hypertension [BA00-BA04]	[40]
Eluxadoline	DMYZ0P1	Major	Decreased clearance of Simeprevir due to the transporter inhibition by Eluxadoline.	Irritable bowel syndrome [DD91]	[39]
GDC-0199	DMH0QKA	Major	Decreased clearance of Simeprevir due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[36]
IPI-145	DMWA24P	Major	Decreased metabolism of Simeprevir caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[36]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[36]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[46]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Simeprevir caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
S-297995	DM26IH8	Moderate	Decreased metabolism of Simeprevir caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[39]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Simeprevir caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[47]
Enzalutamide	DMGL19D	Major	Increased metabolism of Simeprevir caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[40]
Relugolix	DMK7IWL	Major	Decreased clearance of Simeprevir due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[48]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[39]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Simeprevir caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[36]
PRX-321	DM7YWVT	Moderate	Decreased metabolism of Simeprevir caused by PRX-321 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[49]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Simeprevir due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[50]
-----------


⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Shellac	E00695	Not Available	Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Simeprevir 150 mg capsule	150 mg	Oral Capsule	Oral
Simeprevir Sodium eq 150mg base capsule	eq 150mg base	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7367).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
7	Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
8	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
9	Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015 May-Jun;23(2):92-6.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
21	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
22	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
27	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
28	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
29	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
30	The effect of SLCO1B115 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B115. Pharmacogenet Genomics. 2008 May;18(5):424-33.
31	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
32	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
33	FDA Drug Development and Drug Interactions
34	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
35	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
36	Cerner Multum, Inc. "Australian Product Information.".
37	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
38	Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
41	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
43	Canadian Pharmacists Association.
44	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
45	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
46	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
47	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
48	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
49	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
50	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.